Harmony Biosciences (HRMY) vs Trevi Therapeutics (TRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Trevi Therapeutics (TRVI) has outperformed Harmony Biosciences (HRMY) over the past year, gaining 21.5% versus a loss of 5.0%. Over five years, TRVI leads with a +1235.0% price change compared with -13.2% for HRMY. Harmony Biosciences is the larger company by market cap ($1.91 billion vs $1.90 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRMY | TRVI |
|---|---|---|
| Share price | $32.59 | $13.35 |
| Market cap | $1.91B | $1.90B |
| 1-day change | -1.18% | -2.70% |
| YTD return | -12.91% | +6.63% |
| 1-year return | -5.01% | +21.47% |
| 5-year return | -13.21% | +1235.00% |
| P/E ratio (TTM) | 10.79 | — |
| Forward P/E | 5.37 | — |
| EPS (TTM) | $3.02 | $-0.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $868.45M | — |
| Revenue growth (YoY) | +21.51% | — |
| Net income (latest FY) | $158.69M | $-42.76M |
| Gross margin | 77.16% | — |
| Operating margin | 24.00% | — |
| Net margin | 18.27% | — |
| 52-week high | $43.49 | $20.22 |
| 52-week low | $25.90 | $9.82 |
| Distance from 52-week high | -25.06% | -33.98% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +47.53% | +111.09% |
| Average volume | 1.01M | 2.00M |
| Shares outstanding | 58.72M | 142.56M |
| Employees | 293 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRVI has outperformed HRMY by 26.5 percentage points over the past year.
About Harmony Biosciences
HRMY stock →Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
HRMY vs TRVI FAQ
Which is bigger, Harmony Biosciences or Trevi Therapeutics?
Harmony Biosciences (HRMY) is larger, with a market capitalization of $1.91B compared with $1.90B for Trevi Therapeutics (TRVI).
Which stock has performed better over the past year, HRMY or TRVI?
TRVI returned +21.47% over the past 12 months, compared with -5.01% for HRMY (price return, excluding dividends). Past performance does not predict future results.
Are Harmony Biosciences and Trevi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.